June Escara‐Wilke

2.8k total citations · 1 hit paper
25 papers, 1.8k citations indexed

About

June Escara‐Wilke is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, June Escara‐Wilke has authored 25 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in June Escara‐Wilke's work include Bone health and treatments (9 papers), Prostate Cancer Treatment and Research (9 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). June Escara‐Wilke is often cited by papers focused on Bone health and treatments (9 papers), Prostate Cancer Treatment and Research (9 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). June Escara‐Wilke collaborates with scholars based in United States, China and Japan. June Escara‐Wilke's co-authors include Evan T. Keller, Jinlu Dai, Jill M. Keller, Arul M. Chinnaiyan, Vijaya L. Dommeti, Kari Wilder-Romans, Shaomeng Wang, Felix Y. Feng, Irfan A. Asangani and Xiaojun Jing and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

June Escara‐Wilke

24 papers receiving 1.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

2014 737 citations Irfan A. Asangani, Vijaya L. Dommeti et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
June Escara‐Wilke United States	16	1.2k	554	481	333	247	25	1.8k
Daniela S. Daniela Sanchez Bassères Brazil	18	925 0.8×	172 0.3×	379 0.8×	504 1.5×	215 0.9×	37	1.6k
Xiaofen Ye United States	17	1.5k 1.3×	170 0.3×	446 0.9×	167 0.5×	206 0.8×	33	2.1k
Michael Milyavsky Israel	23	1.5k 1.2×	148 0.3×	725 1.5×	456 1.4×	217 0.9×	47	2.1k
Andrea Lunardi United States	20	1.1k 1.0×	242 0.4×	511 1.1×	342 1.0×	61 0.2×	35	1.6k
Teresa Ezponda United States	15	1.4k 1.1×	145 0.3×	323 0.7×	393 1.2×	210 0.9×	29	2.1k
James V. Alvarez United States	21	1.1k 0.9×	636 1.1×	1.1k 2.3×	482 1.4×	54 0.2×	36	2.1k
Manoj Kumar Kashyap United States	23	792 0.7×	171 0.3×	298 0.6×	178 0.5×	72 0.3×	57	1.3k
Martin L. Campbell United States	13	805 0.7×	403 0.7×	515 1.1×	232 0.7×	105 0.4×	18	1.4k
Oskar W. Rokhlin United States	26	1.4k 1.2×	347 0.6×	557 1.2×	583 1.8×	41 0.2×	49	2.0k
Tim Hon Man Chan United States	31	1.8k 1.5×	137 0.2×	647 1.3×	489 1.5×	129 0.5×	66	2.7k

Countries citing papers authored by June Escara‐Wilke

Since Specialization

Citations

This map shows the geographic impact of June Escara‐Wilke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by June Escara‐Wilke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites June Escara‐Wilke more than expected).

Fields of papers citing papers by June Escara‐Wilke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by June Escara‐Wilke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by June Escara‐Wilke. The network helps show where June Escara‐Wilke may publish in the future.

Co-authorship network of co-authors of June Escara‐Wilke

This figure shows the co-authorship network connecting the top 25 collaborators of June Escara‐Wilke. A scholar is included among the top collaborators of June Escara‐Wilke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with June Escara‐Wilke. June Escara‐Wilke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robinson, Tyler, June Escara‐Wilke, Jinlu Dai, Johann Zimmermann, & Evan T. Keller. (2023). A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis. The Prostate. 83(13). 1247–1254. 9 indexed citations

Escara‐Wilke, June, Jinlu Dai, Greg Shelley, et al.. (2021). Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. BMC Cancer. 21(1). 1316–1316. 10 indexed citations

Xu, Jiajie, Tyler Robinson, June Escara‐Wilke, et al.. (2021). Effects of Analgesics on Tumor Growth in Mouse Models of Prostate Cancer Bone Metastasis. Journal of the American Association for Laboratory Animal Science. 60(3). 341–348.

Smith, David C., Stephanie Daignault‐Newton, Petros Grivas, et al.. (2020). Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 18(4). 332–339.e2. 5 indexed citations

Wang, Fuhao, Qiuyan Chen, Jinlu Dai, et al.. (2019). Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. Journal of Cancer Research and Clinical Oncology. 145(8). 1999–2012. 30 indexed citations

Robinson, Tyler, et al.. (2019). Targeted Notch1 inhibition with a Notch1 antibody, OMP‐A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. Journal of Cellular Biochemistry. 120(10). 16946–16955. 6 indexed citations

Zhang, Mi, Jinlu Dai, Jill M. Keller, et al.. (2017). Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Molecular Cancer Research. 15(4). 457–466. 10 indexed citations

Asangani, Irfan A., Kari Wilder-Romans, Vijaya L. Dommeti, et al.. (2016). BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Molecular Cancer Research. 14(4). 324–331. 127 indexed citations

Asangani, Irfan A., Vijaya L. Dommeti, Xiaoju Wang, et al.. (2014). Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 510(7504). 278–282. 737 indexed citations breakdown →

10.

Escara‐Wilke, June, Jill M. Keller, Kathleen M. Woods Ignatoski, et al.. (2014). Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer. The Prostate. 75(3). 292–302. 16 indexed citations

11.

Escara‐Wilke, June, Kam C. Yeung, & Evan T. Keller. (2012). Raf kinase inhibitor protein (RKIP) in cancer. Cancer and Metastasis Reviews. 31(3-4). 615–620. 67 indexed citations

12.

Arredouani, Mohamed S., Stephanie Tseng-Rogenski, Brent K. Hollenbeck, et al.. (2010). Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic mice. The Prostate. 70(9). 1002–1011. 22 indexed citations

13.

Dai, Jinlu, Christopher L. Hall, June Escara‐Wilke, et al.. (2008). Prostate Cancer Induces Bone Metastasis through Wnt-Induced Bone Morphogenetic Protein-Dependent and Independent Mechanisms. Cancer Research. 68(14). 5785–5794. 119 indexed citations

14.

Ignatoski, Kathleen M. Woods, June Escara‐Wilke, Xiaohua Zhang, et al.. (2008). Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. Journal of Interferon & Cytokine Research. 29(2). 105–111. 22 indexed citations

15.

Ignatoski, Kathleen M. Woods, June Escara‐Wilke, William C. Dougall, et al.. (2008). RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. The Prostate. 68(8). 820–829. 23 indexed citations

16.

Keller, Jill M., June Escara‐Wilke, & Evan T. Keller. (2008). Heat stress-induced heat shock protein 70 expression is dependent on ERK activation in zebrafish (Danio rerio) cells. Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology. 150(3). 307–314. 52 indexed citations

17.

Yu, Chunyan, Zhi Yao, Jinlu Dai, et al.. (2007). Aldehyde dehydrogenase is a marker of prostate cancer stem cell-like cells in cell lines. Cancer Research. 67. 1300–1300. 1 indexed citations

18.

Keller, Evan T., Jinlu Dai, June Escara‐Wilke, et al.. (2007). New trends in the treatment of bone metastasis. Journal of Cellular Biochemistry. 102(5). 1095–1102. 18 indexed citations

19.

Kryczek, Ilona, Shuang Wei, Linhua Vatan, et al.. (2007). Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. The Journal of Immunology. 179(3). 1423–1426. 145 indexed citations

20.

Dierick, Herman A., et al.. (1997). Immunocytochemical Localization of the Menkes Copper Transport Protein (ATP7A) to the Trans-Golgi Network. Human Molecular Genetics. 6(3). 409–416. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact